Platinum-resistant Recurrent Clear Cell Ovarian Cancer

Oncology
2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Zai Lab
Zai LabCA - South SF
1 program
1
NiraparibPhase 21 trial
Active Trials
NCT05130515Completed6Est. Jan 2023
CT
1 program
1
NiraparibPhase 2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Zai LabNiraparib

Clinical Trials (1)

Total enrollment: 6 patients across 1 trials

NCT05130515Zai LabNiraparib

Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.

Start: Dec 2021Est. completion: Jan 20236 patients
Phase 2Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
2h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
2h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)